Exploring current opportunities in precision medicine
Genomics and biodata present us with significant new opportunities, but how can we best realise their commercial value and maximise positive impact on healthcare?
Over the past decade, we have seen an acceleration in genomics research output and its application into biomedical technologies. Despite this, pathways towards commercialising early-stage genomics-based opportunities are not yet clear. In part, this is due to the fact that the regulatory environment, articulation of health economics and technological advances are only just beginning to emerge.
A Scientific Committee composed of Sanger, Repositive, Medicines Discovery Catapult, and Advanced Courses and Scientific Conferences team created and hosted a unique two-day interactive workshop tailored to the needs and challenges faced by professionals involved in the translation of early-stage technologies.